![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer Wins FDA Fast Track for Duchenne Muscular Dystrophy Treatment
Pfizer Wins FDA Fast Track for Duchenne Muscular Dystrophy Treatment
October 2, 2020
Pfizer has secured a Fast-Track designation from the FDA for its investigational gene therapy PF-06939926 for the treatment of Duchenne muscular dystrophy (DMD).
DMD is a life-threatening disease brought about by mutations in the gene-encoding dystrophin protein.
The fast-track approval was based on phase 1 trial data suggesting that intravenous administration was effective in sustaining dystrophin levels over the course of a year.
Pfizer plans to launch phase 3 testing immediately, a company spokesperson said.
Upcoming Events
-
21Oct